1-甲基-3,6-(1H,2H)哌嗪二酮 | 5436-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1-甲基-3,6-(1H,2H)哌嗪二酮
• 中文别名: 1-甲基-3,6-吡嗪二酮
• 英文名称: 1-methyl-3,6-(1H,2H)-pyridazinedione
• 英文别名: N-Methylmaleinsaeurehydrazid；1-Methylpyridazin-3,6-dion；1-Methyl-1,2,3,6-tetrahydro-pyridazindion-3,6；1-Methyl-3.6-dioxo-1.2.3.6-tetrahydro-pyridazin；1-methyl-1,2-dihydro-pyridazine-3,6-dione；1-Methyl-1,2-dihydro-pyridazin-3,6-dion；2-methyl-1H-pyridazine-3,6-dione；3-Hydroxy-1-methylpyridazin-6(1H)-one
• CAS: 5436-01-1
• 化学式: C₅H₆N₂O₂
• mdl: MFCD00234108
• 分子量: 126.115
• InChiKey: UAECOHJYXUJDOF-UHFFFAOYSA-N

物化性质

• 熔点：
  210-212 °C
• 沸点：
  234.21°C (rough estimate)
• 密度：
  1.3541 (rough estimate)
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R44,R20/21/22,R36/37/38
• 海关编码：
  2933990090
• 储存条件：
  常温、避光、存放在阴凉干燥处，并密封保存。

SDS

Name:	1-Methyl-3 6-(1H 2H)-pyridazinedione Material Safety Data Sheet
Synonym:
CAS:	5436-01-1

Section 1 - Chemical Product MSDS Name:1-Methyl-3 6-(1H 2H)-pyridazinedione Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5436-01-1	1-Methyl-3,6-(1H,2H)-pyridazinedione		unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5436-01-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 210 - 212 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H6N2O2
Molecular Weight: 126.12

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5436-01-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-3,6-(1H,2H)-pyridazinedione - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5436-01-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5436-01-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5436-01-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-3,6-(1H,2H)哌嗪二酮 在 三氯氧磷 作用下， 生成 6-氯-2-甲基吡嗪-3(2H)-酮
  参考文献：
  名称：

  杂环系列中的药用化学研究。8.沟通。哒嗪V.环状马来酸酰肼系列中的烷基化和重排

  摘要：

  1.研究了马来酸及其某些衍生物的环状酰肼和苯酰肼与硫酸二甲酯的反应，并确定了反应产物的结构。

  DOI：

  10.1002/hlca.19540370325
• 作为产物：
  描述：

  抑芽丹 在 sodium hydroxide 、 硫酸二甲酯 作用下， 生成 1-甲基-3,6-(1H,2H)哌嗪二酮
  参考文献：
  名称：

  杂环系列中的药用化学研究。8.沟通。哒嗪V.环状马来酸酰肼系列中的烷基化和重排

  摘要：

  1.研究了马来酸及其某些衍生物的环状酰肼和苯酰肼与硫酸二甲酯的反应，并确定了反应产物的结构。

  DOI：

  10.1002/hlca.19540370325
• 作为试剂：
  描述：

  1-甲基-3,6-(1H,2H)哌嗪二酮 、 (3S,4S)-6-(3-tert-Butyldimethylsilyloxyphenyl)sulphonyl-3,4-dihydro-3,4-epoxy-2,2,3-trimethyl-2H-benzo[b]pyran 在 1-甲基-3,6-(1H,2H)哌嗪二酮 作用下， 生成 (3S,4R)-3,4-dihydro-4-(2,3-dihydro-2-methyl-3-oxo-pyridazin-6-yl)oxy-3-hydroxy-6-(3-hydroxyphenyl)suphonyl-2,2,3-trimethyl-2H-benzo[b]pyran
  参考文献：
  名称：

  Benzopyrans

  摘要：

  该化合物的式子为：##STR1## 或其药学上可接受的盐，其中X，O R，R.sup.1，R.sup.2，R.sup.3和R.sup.4在说明书中有定义；包含这种化合物的组合物；制备这种化合物所使用的中间体；以及治疗与平滑肌张力和/或运动异常相关的疾病的方法，例如慢性阻塞性气道疾病、哮喘、尿失禁、肠易激综合症、结肠憩室病、食管失弛缓症和高血压。

  公开号：

  US06071938A1

文献信息

• INHIBITORS OF FLAVIVIRIDAE VIRUSES
  申请人：Canales Eda

  公开号：US20110020278A1

  公开（公告）日：2011-01-27

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

  提供的是I式化合物： 及其药用可接受的盐和酯。所提供的化合物、组合物和方法对于治疗黄病毒科病毒感染，特别是丙型肝炎感染，是有用的。
• Benzopyran derivatives
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US05874446A1

  公开（公告）日：1999-02-23

  Novel benzopyran and benzoxazine derivatives represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2 represent a lower haloalkyl group, R.sub.3 represents a hydrogen atom, etc., R.sub.4 represents a heterocyclic group or A--O-- wherein A represents a cyclic structure, etc., R.sub.5 and R.sub.6 represent a lower haloalkyl, X represents .dbd.N--, N.fwdarw.O, etc, are disclosed. These compounds exhibit K.sup.+ channel opening activating and can be widely used as an anti-asthma drug, an anti-epilepsy drug, etc.

  新型苯并吡喃和苯并噁嗪衍生物的一般公式表示为：##STR1##其中R.sub.1和R.sub.2代表较低的卤代烷基，R.sub.3代表氢原子，等等，R.sub.4代表杂环基或A--O--，其中A代表环状结构，等等，R.sub.5和R.sub.6代表较低的卤代烷基，X代表.dbd.N--，N.fwdarw.O等。这些化合物表现出K.sup.+通道开放激活作用，可广泛用作抗哮喘药物、抗癫痫药物等。
• 五元杂芳衍生物及其制备方法和用途
  申请人：广东东阳光药业有限公司

  公开号：CN113072546A

  公开（公告）日：2021-07-06

  本发明属于药物技术领域，具体涉及一类五元杂芳化合物及其组合物、制备方法和用途。所述化合物或组合物可作为维甲酸相关孤核受体γt(Retinoid‑related orphan receptor gamma t,RORγt)的抑制剂。本发明还涉及制备该类化合物和组合物的方法，以及它们在治疗或预防哺乳动物，特别是人类的由RORγt介导的癌症、炎症或自身免疫疾病的用途。
• GPR119 Receptor Agonists
  申请人：Erickson Shawn David

  公开号：US20090286812A1

  公开（公告）日：2009-11-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  提供以下公式(I)的化合物： 以及可药用的接受盐，其中取代基如说明书中所披露。这些化合物以及含有它们的药物组合物可用于治疗代谢性疾病和障碍，例如，2型糖尿病。
• [EN] BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES<br/>[FR] COMPOSÉS DE PYRIDINE BICYCLIQUES FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASES TAM
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019113190A1

  公开（公告）日：2019-06-13

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

  本文提供了Formula (I)的化合物及其立体异构体、互变异构体和药用可接受的盐，其中环A、X1、X2、X3、R1、R2和R3如本文所定义，这些化合物是一种或多种TAM激酶的抑制剂，并且在治疗和预防可以用TAM激酶抑制剂治疗的疾病中非常有用。